ArticleInternational urology and nephrology2014
Capilliposide C derived from Lysimachia capillipes Hemsl inhibits growth of human prostate cancer PC3 cells by targeting caspase and MAPK pathways.
Article in International urology and nephrology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 19 citations in OpenAlex.
- Capilliposide A attenuates diabetic nephropathy via modulation of NF-κB/TLR4 and apoptotic pathways.Scientific reports · 2025Article
- In-depth LC-MS andFrontiers in pharmacology · 2024Article
- Capilliposide fromChinese herbal medicines · 2022Article
- Capilliposide C fromFrontiers in oncology · 2021Article
- Marine alkaloid monanchoxymycalin C: a new specific activator of JNK1/2 kinase with anticancer properties.Scientific reports · 2020Article
- In Vitro and In Situ Characterization of the Intestinal Absorption of Capilliposide B and Capilliposide C fromMolecules (Basel, Switzerland) · 2019Article
- Metabolic Stability and Metabolite Characterization of Capilliposide B and Capilliposide C by LC⁻QTRAP⁻MS/MS.Pharmaceutics · 2018Article
- Capilliposide C Sensitizes Esophageal Squamous Carcinoma Cells to Oxaliplatin by Inducing Apoptosis Through the PI3K/Akt/mTOR Pathway.Medical science monitor : international medical journal of experimental and clinical research · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer, a common malignant tumor of the genitourinary system among elderly males, is difficult to cure. Capilliposide C (CPS-C) is a novel oleanane triterpenoid saponin derived from Lysimachia capillipes Hemsl. Although CPS-C had been investigated in gastric cancer BGC-823 cells, prostate cancer PC3 cells, and ovarian cancer SK-OV-3 cells in nude mice in a dose-dependent manner without overt toxicity, its mechanism in the cancer cells has not been further studied. In the current study, PC3-cell-line-based in vitro models were used to explore the anti-cancer effect and mechanism of CPS-C. The results of cell viability assays showed that CPS-C exhibited dose- and time-dependent cytotoxicity against the prostate cancer cell lines PC3 and DU145. Observations using optical and electron microscope suggested the cytotoxicity of CPS-C. CPS-C-induced apoptosis was confirmed by the activation of caspases, down-regulation of Bcl-2, JNK, and P38α/β, and up-regulation of Bax, p-JNK, and p-P38. Results showed that CPS-C exhibits high toxicity toward two prostate cancer cells in vitro. Therefore, CPS-C may have great potential in the prevention and treatment of human prostate cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.